Literature DB >> 19247023

Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study.

Antonio Toniato1, Isabella Merante-Boschin, Giuseppe Opocher, Maria R Pelizzo, Francesca Schiavi, Enzo Ballotta.   

Abstract

OBJECTIVE: To compare the clinical outcome of patients with subclinical Cushing syndrome (SCS) due to an adrenal incidentaloma (the autonomous hypersecretion of a small amount of cortisol, which is not enough to cause clinically-evident disease) who underwent surgery or were managed conservatively. SUMMARY BACKGROUND DATA: The most appropriate management of SCS patients is controversial, either adrenalectomy or close follow-up being recommended for their treatment.
METHODS: Over a 15-year period, 45 SCS patients were randomly selected to undergo surgery (n = 23) or conservative management (n = 22). All surgical procedures were laparoscopic adrenalectomies performed by the same surgeon. All patients were followed up (mean, 7.7 years; range, 2-17 years) clinically by 2 experienced endocrinologists 6 and 12 months after surgery and then yearly, or yearly after joining the trial, particularly monitoring diabetes mellitus (DM), arterial hypertension, hyperlipidemia, obesity, and osteoporosis. The study end point was the clinical outcome of SCS patients who underwent adrenalectomy versus those managed conservatively.
RESULTS: All 23 patients in the surgical arm had elective surgery. Another 3 patients randomly assigned to conservative management crossed over to the surgical group due to an increasing adrenal mass >3.5 cm. In the surgical group, DM normalized or improved in 62.5% of patients (5 of 8), hypertension in 67% (12 of 18), hyperlipidemia in 37.5% (3 of 8), and obesity in 50% (3 of 6). No changes in bone parameters were seen after surgery in SCS patients with osteoporosis. On the other hand, some worsening of DM, hypertension, and hyperlipidemia was noted in conservatively-managed patients.
CONCLUSIONS: Based on the results of this study, laparoscopic adrenalectomy performed by skilled surgeons appears more beneficial than conservative management for SCS patients complying with our selection criteria. This trial is registered with Australian Clinical Trials Registry number, ANZCTR12608000567325.

Entities:  

Mesh:

Year:  2009        PMID: 19247023     DOI: 10.1097/SLA.0b013e31819a47d2

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  53 in total

1.  Management of adrenal incidentaloma by laparoscopic transperitoneal anterior and submesocolic approach.

Authors:  Alessandro M Paganini; Mario Guerrieri; Andrea Balla; Silvia Quaresima; Andrea M Isidori; Franco Iafrate; Giancarlo D'Ambrosio; Giovanni Lezoche; Emanuele Lezoche
Journal:  Langenbecks Arch Surg       Date:  2015-12-18       Impact factor: 3.445

Review 2.  Pros and cons of screening for occult Cushing syndrome.

Authors:  Antoine Tabarin; Paul Perez
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

3.  Primary adrenal hypercortisolism: minimally invasive surgical treatment or medical therapy? A retrospective study with long-term follow-up evaluation.

Authors:  Mario Guerrieri; Roberto Campagnacci; Andrea Patrizi; Chiara Romiti; Giorgio Arnaldi; Marco Boscaro
Journal:  Surg Endosc       Date:  2010-03-25       Impact factor: 4.584

4.  Guidelines for the management of the incidentally discovered adrenal mass.

Authors:  Anil Kapoor; Topher Morris; Ryan Rebello
Journal:  Can Urol Assoc J       Date:  2011-08       Impact factor: 1.862

Review 5.  Management of Adrenal Masses.

Authors:  Hattangadi Sanjay Bhat; Balagopal Nair Tiyadath
Journal:  Indian J Surg Oncol       Date:  2016-12-17

Review 6.  Surgical management of adrenocortical tumours.

Authors:  Barbra S Miller; Gerard M Doherty
Journal:  Nat Rev Endocrinol       Date:  2014-03-18       Impact factor: 43.330

7.  The role of adrenal scintigraphy in the diagnosis of subclinical Cushing's syndrome and the prediction of post-surgical hypoadrenalism.

Authors:  Maria Pia Ricciato; Vincenzo Di Donna; Germano Perotti; Alfredo Pontecorvi; Rocco Bellantone; Salvatore M Corsello
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

8.  GH secretion reserve in subclinical hypercortisolism.

Authors:  Serena Palmieri; Valentina Morelli; Antonio Stefano Salcuni; Cristina Eller-Vainicher; Elisa Cairoli; Volha V Zhukouskaya; Paolo Beck-Peccoz; Alfredo Scillitani; Iacopo Chiodini
Journal:  Pituitary       Date:  2014-10       Impact factor: 4.107

Review 9.  [Adrenal incidentaloma : Diagnostic and therapeutic concept from an endocrinological perspective].

Authors:  N Unger
Journal:  Chirurg       Date:  2019-01       Impact factor: 0.955

10.  MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors.

Authors:  Dhaval Patel; Myriem Boufraqech; Meenu Jain; Lisa Zhang; Mei He; Krisana Gesuwan; Neelam Gulati; Naris Nilubol; Tito Fojo; Electron Kebebew
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.